Stock Traders Buy Large Volume of Sanofi Call Options (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) was the target of some unusual options trading on Thursday. Traders bought 4,046 call options on the company. This is an increase of approximately 74% compared to the typical volume of 2,321 call options.

Sanofi Price Performance

SNY stock opened at $43.08 on Friday. The company has a 50 day simple moving average of $43.43 and a 200 day simple moving average of $45.21. The stock has a market cap of $104.44 billion, a price-to-earnings ratio of 22.55, a P/E/G ratio of 1.08 and a beta of 0.34. Sanofi has a 1 year low of $40.89 and a 1 year high of $52.68. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Flagship Harbor Advisors LLC acquired a new stake in shares of Sanofi during the 4th quarter valued at $25,000. Physician Wealth Advisors Inc. grew its position in Sanofi by 180.5% during the 1st quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock worth $28,000 after acquiring an additional 379 shares during the last quarter. Leonteq Securities AG increased its holdings in Sanofi by 95.8% in the 1st quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after purchasing an additional 297 shares in the last quarter. Western Wealth Management LLC acquired a new position in Sanofi in the 1st quarter worth about $29,000. Finally, Measured Wealth Private Client Group LLC bought a new position in Sanofi in the third quarter valued at about $29,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SNY has been the subject of a number of recent analyst reports. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Saturday. Citigroup restated a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price for the company. in a research note on Monday, April 20th. Morgan Stanley set a $49.00 target price on Sanofi in a report on Wednesday, July 8th. Finally, Argus upgraded Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, Sanofi presently has a consensus rating of “Hold” and an average target price of $49.50.

Sanofi News Summary

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi reported second-quarter earnings of $1.19 per share, exceeding the $1.10 analyst consensus, while revenue rose 16% year over year to $14.04 billion, above expectations of $13.02 billion. Sanofi quarterly earnings report
• Positive Sentiment: Strong demand for blockbuster immunology drug Dupixent drove the results, with quarterly sales surpassing €5 billion for the first time. The performance led Sanofi to raise its 2026 outlook, targeting roughly 10% sales growth excluding currency effects and slightly faster growth in business earnings per share. Sanofi raises sales outlook on Dupixent strength
• Neutral Sentiment: Unusually high options activity showed traders purchased 4,046 call options, 74% above average daily volume. This may indicate increased bullish speculation, but it does not necessarily signal a change in the company’s fundamentals.
• Negative Sentiment: Management acknowledged that weak decision-making and execution hurt the pipeline. The new CEO plans to overhaul and prioritize R&D, raising concerns about the timing and strength of future product launches. Sanofi discusses pipeline and R&D discipline
• Negative Sentiment: The positive earnings and guidance news was overshadowed by pipeline setbacks, leaving investors focused on whether Dupixent’s momentum can offset longer-term portfolio risks. Sanofi beats earnings but faces pipeline setbacks

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.